Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 89, Issue 2, 2010, Pages 147-154

  Nakhai Pour, H R ^a,b,c   Rey, E ^a,b   Berard A ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Antihypertensive medication; Major congenital malformation; Pregnancy; SGA; Small for gestational age newborns

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; CONGENITAL DISORDER; CONGENITAL MALFORMATION; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HUMAN; MALE; MATERNAL HYPERTENSION; NEWBORN; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; THIRD TRIMESTER PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIHYPERTENSIVE AGENTS; BIRTH WEIGHT; CANADA; CASE-CONTROL STUDIES; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HUMANS; HYPERTENSION; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 77951705521     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20238     Document Type: Article

References (54)

1. Aagaard-Tillery KM, Porter TF, Lane RH, Varner MW, Lacoursiere DY. 2008. In utero tobacco exposure is associated with modified effects of maternal factors on fetal growth. Am J Obstet Gynecol 198:66.e1-66.e6.
2. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. 2007. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 24:CD002252. (Pubitemid 351820393)
3. Afifi Y, Churchill D. 2003. Pharmacological treatment of hypertension in pregnancy. Curr Pharm Des 9:1745-1753.
4. Arias F, Zamora J. 1979. Antihypertensive treatment and pregnancy outcome in patients with mild chronic hypertension. Obstet Gynecol 53:489-494. (Pubitemid 9125419)
5. Beckman D, Brent R. 1984. Mechanism of teratogenesis. Annu Rev Pharmacol Toxicol 24:483-500.
6. Bérard A, Ramos E. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Malform Res B 80:18-27. (Pubitemid 46303265)
7. Bernstein P, Divon M. 1997. Etiologies of fetal growth restriction. Clin Obstet Gynecol 40:723-729.
8. Blais L, Desgagne A, LeLorier J. 2000. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363-2368.
9. Briggs G, Freeman R, Yaf fe S. 2002. Drugs in pregnancy and lactation: reference guide to fetal and neonatal risk. Philadelphia: Lippincott Williams and Wilkins.
10. Butters L, Kennedy S, Rubin P. 1990. Atenolol in essential hypertension during pregnancy. BMJ 301:587-589.
11. Campbell D, MacGillivray I. 1975. The effect of a low calorie diet or a thiazide diuretic on the incidence of pre-eclampsia and on birth weight. Br J Obstet Gynaecol 82:572-577.
12. Caraman PL, Miton A, Hurault de Ligny B, Kessler M, Boutroy MJ, Schweitzer M, Brocard O, Ragage JP, Netter P. 1984. Pregnancy under captopril. Therapie 39:59-62.
13. Caton AR, Bell EM, Druschel CM, Werler MM, Mitchell AA, Browne ML, McNutt LA, Romitti PA, Olney RS, Correa A. National Birth Defects Prevention Study. 2008. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A 82:34-40.
14. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, McNutt LA, Romitti PA, Mitchell AA, Olney RS, Correa A. 2009. National Birth Defects Prevention Study, 2009. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 54:63-70.
15. Catov JM, Nohr EA, Olsen J, Ness RB. 2008. Chronic hypertension related to risk for preterm and term small for gestational age births. Obstet Gynecol 112:290-296.
16. Collins R, Yusuf S, Peto R. 1985. Overview of randomized trials of diuretics in pregnancy. BMJ 290:17-23. (Pubitemid 15075976)
17. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. 2006. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354:2443-2451. (Pubitemid 43855047)
18. Easterling TR, Brateng D, Schmucker B, Brown Z, Millard SP. 1999. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 93:725-733. (Pubitemid 29190671)
19. Ferrer RL, Sibai BM, Mulrow CD, Chiquette E, Stevens KR, Cornell J. 2000. Management of mild chronic hypertension during pregnancy: a review. Obstet Gynecol 96:849-860.
20. Fiocchi R, Lijnen P, Fagard R, Staessen J, Amery A, Van Assche F, Spitz B, Rademaker M. 1984. Captopril during pregnancy. Lancet 2:1153.
21. Glover DD, Amonkar M, Rybeck BF, Tracy TS. 2003. Prescription, over-the-counter and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol 188:1039-1045. (Pubitemid 36530060)
22. Gruppo di Studio Ipertensione in Gravidanza. 1998. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br J Obstet Gynaecol 105:718-722.
23. Haelterman E, Breart G, Paris-Liado J, Dramaix M, Tchobroutsky C. 1997. Effect of uncomplicated chronic hypertension on the risk of small-for- gestational age birth. Am J Epidemiol 145:689-695. (Pubitemid 27175280)
24. Heinonen O, Slone R, Shapiro S. 1977. Birth malformation and drugs in pregnancy. MA: Publishing Sciences Group Littleton.
25. Jones H. 1973. Intrauterine ototoxicity. A case report and review of literature. J Natl Med Assoc 65:201-203.
26. Kramer MS, Platt R, Msc HY, McNamara H, Usher RH. 1999. Are all growth-restricted newborns created equal(ly). Pediatrics 103:599-602. (Pubitemid 29274507)
27. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, Blondel B, Breart G, Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance. 2001. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 108:E35.
28. Kulaga S, Bérard A. 2010. Validity of the diagnostic codes for congenital malformations present in the RAMQ and MedEcho databases. Can J Obstet Gynecol; in press.
29. Kulaga S, Zargarzadeh A, Bérard A. 2009. Prescription drugs with recognized fetotoxic or teratogenic potential filled during pregnancy. BJOG 116:1788-1795.
30. Levy AR, Mayo NE, Grimard G. 1995. Rates of transcervical and pertrochanteric hip fractures in the province of Quebec, Canada, 1981-1992. Am J Epidemiol 142:428-436.
31. Levy-Marchal C, Jaquet D. 2004. Long-term metabolic consequences of being born small for gestational age. Pediatric Diabetes 5:147-153. (Pubitemid 39405987)
32. Luo ZC, Wilkins R, Kramer MS; Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. 2006. Effect of neighbourhood income and maternal education on birth outcomes: a population-based study. CMAJ 174:1415-1420.
33. Lydakis C, Lip G, Beevers M, Beevers D. 1999. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 12:541-547. (Pubitemid 29268384)
34. Magee L. 2001. Treating hypertension in women of child-bearing age and during pregnancy. Drug Saf 24:457-474. (Pubitemid 32458080)
35. Magee LA, Schick B, Donnenfeld AE, Sage SR, Conover B, Cook L, McElhatton PR, Schmidt MA, Koren G. 1996. The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study. Am J Obstet Gynecol 174:823-828. (Pubitemid 26111652)
36. Magee LA, Elran E, Bull SB, Logan A, Koren G. 2000. Risks and benefits of [beta]-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol Reprod Biol 88:15-26. (Pubitemid 30009366)
37. Mcbride W. 1963. The teratogenic action of drugs. Med J Aust 2:689-692.
38. Montan S, Anandakumar C, Arulkumaran S, Ingemarsson I, Ratnam S. 1993. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol 168:152-156. (Pubitemid 23047632)
39. Nakhai-Pour HR, Rey E, Bérard A. 2009. Discontinuation of antihypertensive drug use during pregnancy and the risk of pre-eclampsia and eclampsia among women with chronic hypertension. Am J Obstet Gynecol 201:180.e1-8
40. Ofori B, Oraichi D, Blais L, Rey E, Bérard A. 2006. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: a nested case-control study. Birth Malform Res B 77:268-279. (Pubitemid 44484020)
41. Ofori B, Rey E, Bérard A. 2007. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 64:496-509. (Pubitemid 47404298)
42. Quan A. 2006. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Dev 82:23-28. (Pubitemid 43163036)
43. Ramos E, St-André M, Rey E, Oraichi D, Bérard A. 2008. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 192:344-350. (Pubitemid 351692378)
44. Rayburn WF. 2007. Maternal and fetal effects from substance use. Clinics Perinatol 34:559-571.
45. Redman C. 1977. The use of antihypertensive drugs in hypertension in pregnancy. Clin Obstet Gynaecol 4:685-705. (Pubitemid 8234463)
46. Rey E, LeLorier J, Burgess E, Lange I, Leduc L. 1997. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ 157:1245-1254.
47. Schardein JL. 2000. Cardiovascular-renal drugs. Chemically induced birth malformations. New York: Marcel Dekker, Inc.
48. Sibai BM. 1996. Treatment of hypertension in pregnant women. N Engl J Med 335:257-265.
49. Sibai B, Grossman RA, Grossman HG. 1984. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol 150:831-835. (Pubitemid 15237763)
50. Tamblyn R, Lavoie G, Petrella L, Monette J. 1995. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48:999-1009.
51. Vilain A, Otis S, Forget A, Blais L. 2008. Agreement between administrative databases and medical charts for pregnancy-related variables among asthmatic women. Pharmacoepidemiol Drug Safety 17:345-353. (Pubitemid 351566350)
52. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. 2000. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 355:87-92. (Pubitemid 30068551)
53. Worsham FJ, Beckman E, Mitchell E. 1978. Sacrococcygeal teratoma in a neonate. Association with maternal use of acetazolamide. JAMA 240:251-252.
54. World Health Organization. 1997. International classification of diseases. Geneva: WHO.